Santoni, N., Melo, T., Aguirre, A. R., Veiga, D., & Souza, C. (2017). Cost-effectiveness of afatinib versus pemetrexed plus cisplatin, erlotinib and gefitinib as first line treatment in patients with locally advanced or metastatic epidermal growth factor receptor mutation (EFGR+) non-small cell lung cancer in the Brazil. Jornal Brasileiro De Economia Da Saúde, 9(1), 73–82. https://doi.org/10.21115/JBES.v9.n1.p73-82